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Summary
Background The epilepsy prevalence in Latin America and the Caribbean (LAC) had remained high over the last 20
years. Data on the burden of epilepsy are needed for healthcare planning and resource allocation. However, no systematic analysis had been performed for epilepsy burden in LAC.
Methods We extracted data of all LAC countries from the Global Burden of Disease (GBD) study from 1990 to 2019.
Epilepsy burden was measured as prevalence, mortality, and disability-adjusted life-years (DALYs; defined by the
sum of years of life lost [YLLs] for premature mortality and years lived with disability [YLDs]), by age, sex, year, and
country. Absolute numbers, rates, and 95% uncertainty intervals were reported. We performed correlational analyses
among burden metrics and Socio-demographic Index (SDI).
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Findings The burden of epilepsy decreased around 20% in LAC, led by YLLs reduction. In 2019, 6¢3 million people
were living with active epilepsy of all causes (95% UI 5¢3 - 7¢4), with 3¢22 million (95% UI 2¢21 - 4¢03) and 3¢11 million (95% UI 2¢21 to 4¢03) cases of epilepsy with identifiable aetiology and idiopathic epilepsy, respectively. The
number of DALYs represented the 9¢51% (1.37 million, 95% UI 0¢99 -1¢86) of the global epilepsy burden in 2019.
The age-standardized burden was 175¢9 per 100 000 population (95% UI 119¢4 - 253¢3), which tend to have a
bimodal age distribution (higher in the youth and elderly) and was driven by high YLDs estimates. The burden was
higher in men and older adults, primarily due to high YLLs and mortality. Alcohol use was associated with 17% of
the reported DALYs. The SDI estimates significantly influenced this burden (countries with high SDI have less epilepsy burden and mortality, but not prevalence or disability).
Interpretation The epilepsy burden has decreased in LAC over the past 30 years. Even though, LAC is still ranked as
the third region with the highest global epilepsy burden. This reduction was higher in children, but burden and mortality increased for older adults. The epilepsy burden is disability predominant; however, the mortality-related estimates are still higher than in other regions. Alcohol consumption and countries’ development are important
determinants of this burden. There is an urgent need to improve access to epilepsy care in LAC, particularly for older
adults. Strengthening primary care with online learning and telemedicine tools, and promoting risk factors modification should be prioritized in the region.
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Research in context
Evidence before this study
We searched in PubMed, using the keywords burden of
disease [Title/Abstract] AND epilepsy [Title/Abstract] to
identify published articles addressing the epilepsy burden in Latin America (LAC), without date or language
restrictions (last search May 29, 2021). We also searched
for systematic reviews on epilepsy in Latin America and
the Caribbean (LAC) (Latin America [Title/Abstract] AND
epilepsy [Title/Abstract]). We found 16 studies. Eleven
studies addressed the epilepsy burden globally or
focusing on other regions (seven of them assessed the
global burden, and four studies reported the epilepsy
burden in Europe, USA, and Kenya). Only one study
addressed tangentially the epilepsy burden in LAC but
without country-level analysis and using data until
2016. Besides, we found ﬁve systematic reviews exploring the epilepsy epidemiology in LAC, none of them
estimated burden of disease metrics. Therefore, to date,
no previous studies addressed the epilepsy burden in
LAC, by country, age, sex, and socioeconomic status.
Added value of this study
This trend analysis of the Global Burden of diseases
(GBD) study 2019 is aimed to provide an overview of
the epilepsy impact in LAC over the past 30 years, and
to identify gaps for further public health actions. We
present regional and country-level results of prevalence,
mortality, burden (disability-adjusted life-years [DALYs],
years lived with disability [YLDs], and years of life lost
[YLLs]), and attributable risk factors of all-cause active
epilepsy, active idiopathic epilepsy (i.e., epilepsy of
genetic or unknown origin), and epilepsy with identiﬁable etiology (only prevalence and YLDs). We also
explore the inﬂuence of age, sex, and country’s development status (socio-demographic index [SDI]) on the epilepsy burden in LAC countries.
Implications of all the available evidence
There was a signiﬁcant reduction in the burden of epilepsy from 1990 to 2019 in LAC, driven by a decrease in
premature death rates (YLLs). Even though, in 2019, LAC
is ranked as the third region with the highest worldwide
burden (95% of the global epilepsy burden). The current burden is disability predominant (YLDs), mainly in
men compared to women, and with a bimodal age distribution (the youth and elderly). However, mortality
and disability are increasing alarmingly in older adults
compared to other regions. Besides, we found that 17%

2

of DALYs are associated with alcohol consumption, and
a higher country’s SDI is associated with less burden
due to premature deaths. These results suggest that further improvement can be made in the region by
increasing the access to epilepsy care in low and middle
SDI countries in LAC, strengthening primary care with
online learning and telemedicine tools, and promoting
risk factors modiﬁcations (reduction of alcohol abuse,
sanitation improvement, healthy aging, and cardiovascular risk reduction), especially targeting older adults.
Future GBD studies need to explicitly explore the speciﬁc burden of epilepsy by etiologies (e.g., neurocysticercosis, traumatic brain injury, stroke) that is currently
assessed as one group, also there is a need for assessing
the mortality and YLLs attributed to epilepsy with identiﬁable etiologies..

Introduction
Epilepsy is a global health issue affecting patients without distinction of age, race, and socioeconomic class.1
By 2016, it was estimated that 45¢9 million patients
were living with active epilepsy worldwide.2 This condition is twice as common in low and middle-income
countries as it is in the developed world.2 In Latin
America and the Caribbean (LAC), the estimated lifetime and active epilepsy prevalence were 14¢09 and
9¢06 per 1,000 inhabitants respectively, while the incidence rate was 1¢11 per 1,000 person-year,3 all values
higher than the worldwide estimates.4
However, to understand a disease impact and its epidemiological behaviour, the classic prevalence and incidence estimates are insufficient. Other metrics are
recommended to include not only the disease frequency
but also the degree of health loss produced by the disease (considering deaths and residual disability).5 The
Global Burden of Disease (GBD) study is an example of
this approach. They estimated several metrics such as
disability-adjusted life year (DALY), which is the sum of
the years of life lost (YLL) and the years lived with disability (YLD) due to certain conditions; mortality rates;
and risk factors.6
According to the 2016 GBD study, the global agestandardized epilepsy burden (DALYs) were 182¢6, the
YLDs were 102¢6, and the total amount of epilepsyrelated deaths worldwide was estimated as 126 055.2
The epilepsy burden was higher in men, people in the
extremes of life, and countries with low socio-
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demographic index (SDI). 2This report discussed their
findings at a regional level; thus, it did not present a
comprehensive country-level analysis of low- and middle-SDI regions to further characterize the factors and
trends associated with this high burden.
While the GBD report encourages a differential analysis by regions and countries,7 the available information
on the GBD platform does not allow for further visualization of the LAC region with calculations for changes
and trends over time and neither changes by sex and
age groups, which affects the data usability for regional
prioritization and health policies. Furthermore, the
complex interplay of health determinants in LAC underscores the need for epilepsy burden assessment to
assure an adequate economic, clinical, and scientific
resources allocation in the region. Thus, we aimed to
conduct a trend epidemiological profiling of epilepsy in
LAC using the data provided by the GBD study from
1990 to 2019.

Methods
The Global Burden of Disease Study 2019
The methodology of the GBD Study 2019 had been
described elsewhere.8,9 In summary, the GDB Study
group estimates the burden of disease by performing a
Bayesian meta-regression modelling (using the DisMod-MR 2¢1 software). The modelling is based on i)
available data (population surveys and systematic
reviews with meta-analysis) from countries worldwide,
and ii) predictive estimations for countries with sparse
or no data. The metrics calculated are adjusted for possible confounders (exposure measure of alcohol consumption and pig meat consumption per capita). The
provided metrics are prevalence, mortality, burden metrics (Disability-adjust life years [DALYs], years of life
lost [YLLs], and years lived with disability [YLDs]), and
risk factors.9 Additionally, they reported an indicator of
the country’s socio-economic development called sociodemographic Index (SDI), this indicator is a composite
of the income per capita, the years of school education,
and the fertility rate in women younger than 25 years
old. 9

Latin America and the Caribbean countries
For this analysis, we utilized data from 17 individual
countries that belong to Latin America and the Caribbean region.10 We included the following five subregions proposed by the GBD study11: a) Andean Latin
America (Bolivia, Ecuador y Peru), b) Caribbean (all
islands, including Puerto Rico − we extracted the whole
sub-region since the data of individual countries was
incomplete), c) Central Latin America (Colombia, Costa
Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama and Venezuela), d) Tropical Latin
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America (Brazil, Paraguay), e) Southern Latin America
(Argentina, Chile, and Uruguay).

Epilepsy deﬁnitions
Similar to the global report for epilepsy,2 we report the
GBD study data for overall epilepsy, which includes the
idiopathic and secondary components. For overall epilepsy, the case definition used by the GBD study was
based on the International League Against Epilepsy
(ILAE) Guidelines for Epidemiologic Studies on Epilepsy: two or more unprovoked recurrent seizures with
at least one occurring in the last five years, with or without treatment.12 The diagnostic codes used for epilepsy
were 345 of the ICD-9, and G40 and G41 of the ICD10.13,2
Idiopathic active epilepsy was defined by the GBD
study according to the 1985 ILAE proposal,14 and
included those of genetic or unknown causes.
Data on epilepsy with identifiable aetiology data was
calculated as the subtraction of idiopathic epilepsy from
the overall epilepsy estimate.2 However, the GBD study
provided the complete burden metrics only for idiopathic epilepsy; thus, the main analysis focused on the
idiopathic subgroup.

GBD study metrics deﬁnitions
Disability-adjust life years (DALYs): This metric is calculated as: “the sum of the years of life lost because of premature mortality (YLL) and the years of healthy life lost
due to disability.”6
Years of life lost (YLLs): This metric is calculated as
the number of deaths per age group multiplied for the
remaining years to live according to countries’ life
expectancy based on the GBD standard life table.15
Years lived with disability (YLDs): This is calculated
as: “the number of incident cases in a certain period of
time multiplied by the average of disease duration and
by a weight factor that reflects its severity which ranges
from 0 (perfect health) to 1 (deceased).”6
Deaths: The cause of death is attributed to epilepsy if
in the death certificate the ICD-10 codes G40 or G41
were reported as the cause of death either confirmed or
suspected. The exact mechanism was not available (e.g.,
status epilepticus, accidents associated with seizures, or
sudden unexpected death in epilepsy [SUDEP]).
Risk Factors: The methodology for the calculation of
risk factors is explained in detail elsewhere.16 In summary, the population-attributable fraction (expressed in
percentage) was estimated using data for exposure, relative risk, and a theoretical-minimum exposure level.
This metric is interpreted as the degree of burden
explained by a certain risk factor. For epilepsy, 87 risk
factors were explored, but they only reported results
that showed an association.17
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Data extraction procedure

Role of the funding source

Data was extracted independently by two researchers
from the GBD 2019 database for global and Latin America and the Caribbean region, including a total of 17
countries and five subregions, from 1990 to 2019. We
extracted epilepsy data from two contexts: “impairment”
(for overall epilepsy and epilepsy with identifiable aetiology) and “cause” (for idiopathic epilepsy). We extracted
six metrics per country: SDI, prevalence, mortality,
DALYs, YLLs, and YLDs with their corresponding 95%
uncertainty intervals. The metrics were expressed as
absolute numbers, and relative rates (all ages and agestandardized rates by 100 000 inhabitants. Besides, we
extracted the burden data attributable to risk factors (the
percentage of DALYs associated with a specific risk factor): from the 87 risk factors assessed in the GBD 2019
study, the only risk factor associated with epilepsy burden was alcohol use, hence, it was the only value for
extraction. Finally, we extracted the aforementioned
metrics divided into sub-groups based on age (under 5,
5 to 14, 15 to 49, 50 to 69, and more than 70 years old)
and sex (female and male). The datasets were requested
and downloaded from the open-access GBD study website: http://ghdx.healthdata.org/gbd-results-tool. The
data visualization options available in the GBD platform
are multiple. However, an option to evaluate trends and
changes over time for the complete LAC region, and by
age groups and sex is currently not provided on the website. The data was tabulated and organized in a Microsoft Excel spreadsheet.

This study was self-funded by the authors. No external
source had any role in the study design, data collection,
data analysis, interpretation of the results or writing of
the report.

Statistical analysis
For the descriptive analysis of variables, the absolute
numbers, rates and their 95% uncertainty interval were
extracted and used directly from the GBD platform. For
estimates using numbers, the aggregated geographical
data (LAC overall and subregions) was calculated by
arithmetic summing the countries’ values, while for
age-standardized rates, the weighted arithmetic mean
was used. We calculated the additional estimates percent of change from 1990 to 2019 to compare the overall trends across sub-regions and countries that were
not originally provided in the platform. We manually
calculated the percentage of change by using an arithmetic “rule of three”. Also, the annualized rate of
change from 1990 to 2019 was calculated by subtracting the values from 2019 and 1990, then dividing it by
the number of years (30 years). In both calculations, the
formulas were applied for both the estimates in number
and rates using the data from the GBD study. Moreover,
we performed an exploratory correlational analysis
among burden metrics and the countries’ SDIs using
Spearman’s rank correlation test since we expected nonnormal aggregate data. We considered a 0¢05 significance level for all the analyses. Analyses were conducted
using R version 4¢0¢2.18
4

Results
Prevalence
Our results indicated that in 2019, there were
6,342,165¢7 (95% UI 5,318,849 to 7,415,361¢3) individuals with all-cause epilepsy in LAC, and the age-standardized rate was 817 (95% UI; 649¢7 - 976¢8). A similar
number of cases were attributed to idiopathic cases
(49%) and cases with identifiable aetiology (51%). For
idiopathic epilepsy, there were 3,116,748¢4 patients,
which represented an increase of 44¢3% from 1990. For
epilepsy with identifiable etiology, there were
3,225,417¢3 cases (95% UI 2,218,511¢1 - 4,039,169¢3),
which meant an increase of 107¢8% from 1990. This
prevalence in LAC represented 8¢1% of the global prevalence in 2019. The age-standardized prevalence rate
(per 100 000 population) of epilepsy with identifiable
aetiology in 2019 was 1222¢1 (95% UI, 392¢10 to 416¢8),
which increased from 1990 (10¢8%). Moreover, the
age-standardized prevalence rate (per 100 000 population) of idiopathic epilepsy in 2019 was 411¢9 (95%
UI, 257¢6 to 560), with virtually no changes since
1990 (-0¢0003%). The prevalence rate was similar in
males (410; 95% UI 257¢9 to 555¢9) and females
(413¢70; 9% UI, 256¢9 to 565¢9). The higher prevalence was found in patients of 70 years and older
(664¢5; 95% UI, 413¢2 to 925¢4), followed by the 5to 14-year-old group (419¢4; 95% UI, 229¢5 to 652¢5),
and the 50- to 69-year-old age group (409; 95% UI,
244¢4 to 581¢8).
The region with the highest prevalence rate for all
LAC in 2019 was Central Latin America (573¢4, 95% UI,
410¢7 to 752), the region with the lowest prevalence rate
was Southern Latin America with 327¢9 (95% UI, 153¢9
to 484¢3). Paradoxically, the region with the highest
increment from 1990 to 2019 was Southern Latin
America (+10¢7%), the region with the highest decrement was Tropical Latin America (-13¢7%).
The country with the lowest prevalence rate in
2019 was Argentina with 267¢9 (95% UI, 83¢7 to
428¢9) followed by Uruguay 381¢1 (95% UI, 106¢9 to
612¢2), the country with highest prevalence rate was
Ecuador 659¢7 (95% UI, 177¢4 to 1089¢2). The country with the most incremental change was Panama
(+30¢8%), followed by Uruguay (18¢5%). The countries with the highest decrement were Bolivia
(-20¢9%), and Brazil (-14¢2%).
However, the differences by age or geographical location were not statistically significant due to overlapping
confidence intervals.
www.thelancet.com Vol 8 Month April, 2022
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Mortality
No data on all-cause epilepsy mortality were available;
thus, we calculated estimates only for idiopathic epilepsy. The age-standardized mortality rate (per 100 000
population) due to active idiopathic epilepsy in LAC in
2019 was 1¢25 (95% UI, 1¢1 to 1¢4), a 19% less since
1990. It has decreased constantly since 1990 until
around 2002 and since then has remained steady until
2019. Changes in mortality rates over the years from
1990 to 2019 are presented in Figure 1. In 2019, it was
higher in men (1¢6; 95% UI, 1¢4 to 1¢7) than in women
(0¢9; 95% UI, 0¢8 to 1¢1), similarly that in 1990
(Figure 1).
From 1990 to 2019, it had decreased around 50% in
children under 5 years old. It had remained still in the
age group of 5 to 14 years old, 15- to 49-year-old, and in
the group of 50 to 69 years old. It had a bimodal increment in the 70+ group, it initially decreased from 1990
to 2000, and then increased progressively until 2019.
The progress of mortality rates by years and by age
groups is presented in Figure 2.
The region with the highest age-standardized mortality rate was the Caribbean (2.1; 95% UI, 1.6 to 2¢6) and
the one with the lowest was Southern Latin America
(0¢9; 95% UI, 0¢9 to 1). The country with the highest
mortality rate was Honduras (3¢2; 95% UI, 2¢3 to 4¢4)
followed by Guatemala (2¢7; 95% UI, 2¢2 to 3¢5). The
country with the lowest mortality rate was Argentina
(0¢7; 95% UI, 0¢7 to 0¢8), followed by Peru (0¢8; 95%
UI, 0¢6 to 1¢1). The differences between countries with
the highest and lowest mortality rates were statistically
significant by means of confidence intervals.

Burden of Epilepsy

DALYs. We did not calculate DALYs for all-cause epilepsy and epilepsy with identifiable aetiology since YLLs
estimates were not available, hence, we estimated

DALYs only for idiopathic epilepsy. The total number of
DALYs for idiopathic epilepsy in 2019 was 1,375,066¢9
(95% UI, 997,125¢3 to 1,861,732¢3), which meant an
increase of 13¢6% from 1990. It represented 9¢5% of
the total world DALYS in 2019. The age-standardized
rate of DALYs in LAC was 175¢9 (95% UI, 119¢4 to
253¢3), a 19¢3% less than in 1990. The age-standardized
burden was higher in men (190; 9% UI, 133¢8 to 266¢3)
than in females (162¢57; 9% UI, 105¢8 to 239¢9) in
2019, as it was in 1990 (Figure 1).
In the under 5 years-old groups, DALYs had
decreased by 27%, and both YLDs and YLLs components contributed equally. DALYs were the highest in
the 70+ group, with an 80% component of YLDs
(Figure 2). The rest of the age groups remain still and
high (around 200 DALYs per 100 000 population)
across time. In 2019, the DALYs and its components
have a multimodal behaviour across the lifespan. YLLs
peaked at age under 5 years and had a plateau at 25 to
49 years old, then decreased progressively till 70 years
old, then again has a slow increase until 95 plus years
old (Figure 3). YLDs peaked at 15 to 19 years of age,
decreased until 40−49 years, and increased exponentially to the oldest age group (> 60 years old), this second peak is almost double compared with younger ages
groups (Figure 3).
The region with the higher age-standardized rate was
Central Latin America (249¢5; 95% UI, 178¢6 to 339¢5);
while the region with the lowest rate was Southern Latin
America (131¢9; 95% UI, 77¢7 to 211¢5). The country with
the highest age-standardized rate of DALYs was Ecuador (293¢2; 95% UI, 142¢1 to 496¢3) followed by Guatemala (292¢5; 95% UI, 164¢5 to 465¢7). The countries
with the lowest rate of DALYs were Argentina (110¢9;
95% UI, 56¢9 to 197¢7) and Uruguay (167¢7; 95% UI,
84¢9 to 291¢9) (Figure 4). Those geographical differences presented overlapping confidence intervals. The
total DALYs by country in 1990 and 2019 are presented
in Figure 5.

Figure 1. Age standardized DALYs, YLLs, YLDs and mortality rates (per 100 000 population) in Latin America and the Caribbean from
1990 to 2019. Both sexes (a), women (b), and (c) men.DALYs, Disability-adjusted life years; YLLs, years of life lost; YLDs, years lived
with disability.
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Figure 2. DALYs, YLLs, YLDs and mortality rates (per 100 000 population) by age subgroup in Latin America and the Caribbean from
1990 to 2019.DALYs, Disability-adjusted life years; YLLs, years of life lost; YLDs, years lived with disability.

YLDs. For all-cause epilepsy, the total number of

YLDs was 2,102,737¢4 (95% UI; 1,385,333¢1 −
2,880,854¢3) and the age-standardized rate was 268.6
(95% UI; 172¢7 - 380¢9) for LAC in 2019. Slightly higher
numbers of YLDs were generated by epilepsy with identifiable aetiology (56¢4%) compared to idiopathic cases
(43¢6%). For epilepsy with identifiable aetiology, the
total number of YLDs in LAC in 2019 was 1,185,984¢9
which meant a 110% increment from 1990. The agestandardized rate of YLDs was 419¢3 (283¢8 − 566¢3), a
7¢9% higher than the 1990 rate.
For idiopathic epilepsy, the total number of YLDs in
LAC in 2019 was 916,752¢5 which meant a 19¢5% increment from 1990. Additionally, it represented 11¢8% of
the global YLDs due to epilepsy. The age-standardized
rate of YLDs was 117¢9 (61¢6 − 195¢5), a 15¢8% lower
than the 1990 rate.
The age-standardized rate of YLDs was similar in
men (118¢2; 95% UI, 62¢3 to 194¢7) and in women
(117¢7; 95% UI, 61¢2 to 195¢9). The age groups with a
bigger decrement in YLDs were the 15- to 49-year-old
group and in lesser account the 5-to-14-year group. The
rest of the groups remained still through time.
The region with the higher rate was Central Latin
America (168¢7; 95% UI, 100¢3 to 257¢6); while the
region with the lowest rate was Southern Latin
America (88¢7; 95% UI, 35¢2 to 168¢4). The country

6

with the highest age-standardized rate of YLDs was
Ecuador (200¢8; 95% UI, 49¢9 to 395¢7) followed by
Mexico (184¢9; 95% UI, 108¢1 to 276¢5). The countries with the lowest rate of YLDs were Argentina
(75¢2; 95% UI, 21¢3 to 161¢6) and Uruguay (104¢5;
95% UI, 20¢7 to 226¢8). However, those regional
and by-country differences had overlapping confidence intervals (Figure 4).

YLLs. No YLLs data for all-cause epilepsy were available; thus, we calculated estimates only for idiopathic
epilepsy. In 2019, the total number of YLLs for idiopathic epilepsy in LAC was 458,314¢4, which meant an
increment of 3¢4% from 1990 and represented the
8¢6% of the global YLLs due to epilepsy. The age-standardized rate of YLLs was 58 (95% UI, 51¢9 to 64¢9),
that is a reduction of 25¢5% from the 1990 rate. YLLs
were higher in males (71¢8; 95% UI, 64¢5 to 80) than in
females (44¢9; 95% UI, 38.2 to 52¢4). The biggest
change in YLLs rate was found in the under 5 years in
almost 50%. The smaller rate of YLLs was found in the
5- to 14-year-old group and in the 70+ group in both
groups it had remained still.
The region with the higher rate was the Caribbean
(106¢3; 95% UI, 76¢9 to 134) while the region with the
lowest rate was Southern Latin America (43¢2; 95% UI,
39¢6 to 46¢3). The country with the highest agewww.thelancet.com Vol 8 Month April, 2022
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Figure 3. Trend of DALYs, YLDs, and YLLs rates (per 100 000 population) due to idiopathic epilepsy in LAC across age subgroups,
2019.YLLs, years of life lost; YLDs, years lived with disability. Error bars represent UI 95%.

standardized rate of YLLs was Guatemala (133¢8; 95%
UI, 104¢5 to 171¢3) followed by Honduras (118¢7; 95%
UI, 79¢9 to 167¢6). The countries with the lowest rate of
YLLs were Argentina (35¢6; 95% UI, 31¢9 to 38¢3) and
Peru (40¢5; 95% UI, 28¢6 to 56¢1). However, differences

between countries had overlapping confidence intervals
(Figure 4).
A summary of all the estimates by country and their percentages of change from 1990 to 2019 is presented in
Table 1.

Figure 4. Burden of epilepsy by Country Rank by aged-standardized rates.

www.thelancet.com Vol 8 Month April, 2022
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Figure 5. Geographical assessment: a, b) Age-standardized DALYs rates (per 100 000 population) in Latin America and the Caribbean in 1990 (a) and 2019 (b). c, d) Alcohol use as risk factor of epilepsy burden (age-standardized) in LAC in 1990 (c) and 2019 (d).
The risk factor impact is presented as the percent of associated DALYs.DALYs, Disability-adjusted life years.
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1990
Number (in
thousands) (95% UI)

Age standardized rate
(by 100 000 population) (95% UI)

2019
Number (in
thousands)
- (95% UI)

Changes
Age standardized rate
(by 100 000
population) - (95% UI)

Percentage change
for numbers (95% UI)

Annualised rate of
change, 1990−2019
(in numbers)

Percentage change
for rates (95% UI)

Annualised
rate of change,
1990−2019 (in rates)

Global
Prevalence 15324¢1 (11446¢7 - 19630¢6)

288¢8 (218¢2 - 364¢8)

25111¢1 (19033¢6 - 31433¢0)

326¢3 (247¢8 - 408¢3)

63¢9 (60¢1 - 66¢3)

326¢2 (252¢9 - 393¢4)

13¢0 (11¢9 - 13¢6)

1¢2 (1¢0 - 1¢5)

Deaths

100¢1 (81¢2 - 112¢2)

1¢9 (1¢6 - 2¢2)

114¢0 (100¢2 - 129¢9)

1¢5 (1¢3 - 1¢7)

13¢9 (10¢4 - 15¢8)

0¢5 (0¢2 - 0¢6)

-24¢8 (-30¢7 - -12¢4)

0¢0 (-0¢1 - 0¢2)

DALYs

11285¢6 (8614¢1 - 14136¢6)

204¢3 (157¢6 - 254¢1)

13077¢6 (9986¢7 - 16734¢1)

170¢6 (130¢4 - 218¢3)

15¢9 (12¢9 - 18¢4)

59¢7 (45¢8 - 86¢6)

-16¢5 (-17¢3 - -14¢1)

-1¢1 (-3¢1 - -0¢2)

YLLs

5897¢0 (4542¢8 - 6774¢0)

104¢6 (81¢6 - 119¢2)

5336¢8 (4722¢7 - 6170¢1)

69¢5 (61¢7 - 80¢6)

-9¢5 (-18¢0 - 4¢0)

-18¢7 (-20¢1 - 6¢0)

-33¢6 (-44¢4 - -22¢4)

-1¢2 (-2¢7 - -0¢3)

YLDs

5388¢6 (3355¢7 - 7974¢0)

99¢7 (63¢1 - 146¢1)

7740¢8 (4810¢3 - 11216¢7)

101¢1 (63¢1 - 146¢8)

43¢7 (40¢7 - 48¢3)

78¢4 (48¢5 - 108¢1)

1¢4 (0¢0 - 2¢5)

0¢0 (-0¢2 - 0¢3)
0¢0 (-0¢4 - 0¢8)

Overall Latin America
Prevalence 2159¢3 (1519¢7 - 2872¢8)

411¢9 (268¢6 - 563¢8)

3116¢8 (2218¢5 - 4039¢1)

411¢9 (257¢6 - 560¢0)

44¢3 (40¢6 - 46¢0)

31¢9 (23¢3 - 38¢9)

0¢0 (-4¢1 - 0¢7)

Deaths

7¢6 (6¢9 - 8¢0)

1¢5 (1¢4 - 1¢6)

9¢8 (8¢9 - 11¢1)

1¢3 (1¢1 - 1¢4)

28¢9 (23¢2 - 37¢4)

0¢1 (0¢01 - 0¢5)

-19¢1 (-22¢1 - -14¢6)

0¢0 (-0¢1 - 0¢2)

DALYs

1210¢6 (905¢7 - 1624¢7)

217¢8 (154¢8 - 302¢1)

1375¢1 (997¢1 - 1861¢7)

175¢9 (119¢4 - 253¢3)

13¢6 (10¢1 - 14¢6)

5¢5 (3¢0 - 7¢9)

-19¢3 (-22¢9 - -16¢1)

-1¢4 (-2¢2 - -1¢1)

YLLs

443¢3 (393¢3 - 471¢9)

77¢8 (70¢1 - 81¢9)

458¢3 (404¢9 - 522¢5)

58¢0 (51¢9 - 64¢9)

3¢4 (3¢0 - 10¢7)

0¢5 (0¢2 - 1¢7)

-25¢5 (-28¢0 - -20¢6)

-0¢7 (-1¢6 - -0¢3)

YLDs

767¢2 (460¢9 - 1173¢5)

140¢0 (76¢4 - 224¢1)

916¢8 (537¢9 - 1406¢3)

117¢9 (61¢6 - 195¢5)

19¢5 (16¢7 - 21¢8)

5¢0 (2¢6 - 7¢8)

-15¢8 (-19¢3 - -12¢8)

-0¢7 (-2¢5 - -0¢1)

Prevalence 76¢9 (19¢3 - 127¢2)

232¢2 (58¢3 - 384¢5)

120¢2 (37¢4 - 192¢9)

268¢0 (83¢7 - 428¢9)

56¢4 (51¢7 - 93¢7)

1¢4 (0¢6 - 2¢2)

15¢4 (11¢6 - 43¢5)

1¢2 (0¢8 - 1¢5)

Deaths

251¢9 (228¢0 - 265¢5)

0¢8 (0¢7 - 0¢8)

344¢5 (315¢8 - 366¢3)

0¢7 (0¢7 - 0¢8)

36¢7 (35¢1- 38¢5)

0¢0 (0¢0 - 0¢6)

-7¢7 (-9¢0 - -6¢1)

0¢0 (-0¢3 - 0¢1)

DALYs

37¢7 (18¢7 - 64¢3)

114¢3 (56¢7 - 194¢9)

49¢7 (25¢7 - 88¢5)

110¢9 (56¢9 - 197¢7)

31¢6 (28¢8 - 37¢6)

0¢4 (0¢2 - 0¢8)

-3¢0 (-5¢3 - 0¢5)

-0¢1 (-0¢9 - 0¢1)

YLLs

13¢1 (11¢5 - 13¢9)

40¢1 (35¢1 - 42¢6)

16¢1 (14¢5 - 17¢2)

35¢6 (31¢9 - 38¢3)

22¢8 (20¢5 − 24.0)

0¢1 (0¢1 - 0¢4)

-11¢1 (-18¢9 - -8¢0)

-0¢1 (-0¢5 - 0¢2)

YLDs

24¢6 (05¢7 - 50¢7)

74¢2 (17¢3 - 153¢3)

33¢6 (09¢5 - 71¢9)

75¢2 (21¢3 - 161¢6)

36¢3 (26¢3 − 42.0)

0¢3 (0¢1 - 0¢7)

1¢3 (0¢4 - 9¢7)

0¢0 (-0¢1 - 0¢3)
0¢6 (0¢1 - 0¢9)

High-Income Super Region
Southern Latin America
Argentina

Chile
Prevalence 60¢4 (17¢6 - 103¢0)

449¢4 (131¢5 - 763¢3)

85¢2 (24¢5 - 134¢2)

467¢2 (133¢9 - 737¢6)

41 (39¢3 - 46¢3)

0¢8 (0¢2 - 1¢0)

4¢0 (1¢8 - 8¢4)

Deaths

214¢8 (202¢2 - 226¢9)

1¢7 (1¢6 - 1¢8)

287¢9 (262¢9 - 311¢7)

1¢4 (1¢2 - 1¢5)

34 (30 - 37¢3)

0¢0 (0¢0 - 0¢6)

-21¢3 (-33¢8 - -19¢0)

0¢0 (-0¢2 - 0¢3)

DALYs

30¢2 (15¢7 - 51¢9)

223¢7 (116¢9 - 383¢6)

32¢5 (15¢5 - 56¢5)

176¢5 (81¢6 - 309¢9)

7¢7 (-1¢4 − 9.0)

0¢1 (0¢0 - 0¢2)

-21¢1 (-30¢2 - -19¢2)

-1¢6 (-3¢2 - -0¢5)

YLLs

10¢9 (10¢2 - 11¢5)

80¢8 (75¢9 - 85¢3)

11¢0 (10¢1 - 12¢1)

57¢2 (52¢1 - 63¢7)

1¢2 (-1¢2 - 4¢8)

0¢0 (0¢0 - 0¢8)

-29¢3 (-31¢4 - -25¢3)

-0¢8 (-1¢2 - -0¢3)

YLDs

19¢3 (04¢9 - 40¢9)

142¢9 (36¢5 - 302¢9)

21¢5 (04¢5 - 45¢5)

119¢3 (24¢8 - 253¢2)

11¢4 (-3 - 13¢2)

0¢1 (0¢0 - 0¢2)

-16¢5 (-32¢1 - -11¢4)

-0¢8 (-1¢7 - -0¢4)

Prevalence 10¢1 (2¢8 - 16¢9)

321¢5 (88¢1 - 540¢5)

13¢4 (3¢8 - 21¢4)

381¢1 (106¢9 - 612¢2)

32¢3 (26¢3 - 35¢3)

0¢1 (0¢0 - 0¢1)

18¢5 (13¢3 - 21¢4)

2¢0 (0¢6 - 2¢4)

Deaths

41¢9 (39¢4 - 45¢1)

1¢3 (1¢2 - 1¢4)

61¢3 (52¢5 - 66¢7)

1¢5 (1¢3 - 1¢6)

46¢5 (33¢1 - 48¢0)

0¢0 (0¢0 - 0¢3)

15¢1 (6¢7 - 26¢2)

0¢0 (0¢0 - 0¢3)

DALYs

5¢0 (2¢6 - 8¢8)

161¢2 (82¢5 - 282¢2)

5¢8 (2¢9 - 10¢1)

167¢7 (84¢9 - 291¢9)

16¢1 (15¢7- 16¢5)

0¢0 (0¢0 - 0¢6)

4¢1 (2¢8 - 8¢4)

0¢2 (0¢1 - 0¢3)

YLLs

1¢9 (1¢7 - 2¢0)

59¢9 (56¢0 - 65¢6)

2¢2 (1¢9 - 2¢4)

63¢3 (56¢7 - 70¢4)

19¢8 (14¢6 - 20¢3)

0¢0 (0¢0 - 0¢4)

5¢7 (1¢3 - 7¢3)

0¢1 (0¢0 - 0¢2)

YLDs

3¢2 (0¢7 - 6¢9)

101¢3 (22¢4 - 220¢6)

3¢6 (0¢7 - 7¢8)

104¢5 (20¢7 - 226¢8)

14¢0 (3¢4 − 18¢5)

0¢0 (0¢0 - 0¢1)

3¢1 (-7¢6 - 5¢8)

0¢1 (-0¢1 - 0¢2)

Uruguay

(continued on next page)
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Table 1 (Continued)
1990
Number (in
thousands) (95% UI)

Age standardized rate
(by 100 000 population) (95% UI)

2019
Number (in
thousands)
- (95% UI)

Changes
Age standardized rate
(by 100 000
population) - (95% UI)

Percentage change
for numbers (95% UI)

Annualised rate of
change, 1990−2019
(in numbers)

Percentage change
for rates (95% UI)

Annualised
rate of change,
1990−2019 (in rates)

Latin America and Caribbean Super Region
Caribbean
Prevalence 134¢3 (83¢9 - 187¢9)

383¢5 (238¢9 - 534¢0)

183¢7 (115¢1 - 255¢5)

386¢9 (241¢4 - 537¢9)

36¢8 (36¢0 - 37¢3)

1¢6 (1¢0 - 2¢3)

0¢9 (0¢1 - 1¢7)

0¢1 (-0¢1 - 0¢1)

Deaths

2¢6 (1¢9 - 3¢1)

1002¢1 (791¢2 − 1222.0)

2¢1 (1¢6 - 2¢5)

14¢8 (12¢2 - 25¢7)

0¢0 (0¢0 - 0¢3)

-20¢3 (-26¢8 - -15¢3)

0¢0 (0¢0 - 0¢0)
-1¢3 (-1¢7 - -1¢0)

872¢7 (629¢6 - 1060¢9)

DALYs

96¢7 (68¢0 - 130¢7)

268¢8 (191¢3 - 361¢1)

107¢3 (75¢8 - 145¢5)

228¢9 (160¢2 - 310¢3)

10¢9 (8¢3 - 11¢4)

0¢4 (0¢3 - 0¢5)

-14¢9 (-19¢3 - -12¢1)

YLLs

46¢6 (24¢8 - 74¢1)

131¢5 (70¢8 - 207¢7)

57¢9 (30¢6 - 95¢2)

122¢6 (64¢6 - 202¢9)

24¢1 (23¢1 - 28¢5)

0¢4 (0¢2 - 0¢7)

-6¢8 (-8¢8 - -2¢3)

-0¢3 (-0¢5 - -0¢2)

YLDs

50¢1 (33¢0 - 64¢2)

137¢3 (93¢4 - 173¢0)

49¢4 (36¢4 - 62¢1)

106¢3 (76¢9 - 134¢0)

-1¢3 (-3¢3 - 10¢3)

0¢0 (-0¢1 - 0¢1)

-22¢6 (-27¢7 - -12¢5)

-1¢0 (-1¢5 - -0¢3)

Prevalence 31¢5 (06¢9 - 55¢6)

509¢4 (111¢1 - 899¢7)

47¢1 (11¢7 - 79¢2)

402¢9 (99¢7 - 672¢9)

49¢5 (42¢6 - 69¢6)

0¢5 (0¢2 - 0¢8)

-20¢9 (-25¢2 - -15¢2)

-3¢6 (-7¢6 - -0¢4)

Deaths

197¢5 (134¢1 - 257¢1)

3¢4 (2¢4 - 4¢3)

198¢7 (144¢6 - 259¢6)

1¢9 (1¢4 - 2¢4)

0¢6 (-7¢8 - 1¢0)

0¢0 (0¢0 - 0¢3)

-45¢9 (-53¢9 - -34¢0)

-0¢1 (-0¢2 - 0¢0)

DALYs

25¢4 (13¢7 - 39¢7)

387¢1 (202¢1 - 611¢2)

26¢0 (12¢9 - 43¢5)

219¢9 (108¢0 - 366¢4)

2¢4 (-5¢4 - 9¢5)

0¢0 (0¢0 - 0¢1)

-43¢2 (-46¢5 - -40¢0)

-5¢6 (-8¢2 - -3¢1)

YLLs

12¢2 (07¢8 - 16¢4)

176¢3 (120¢5 - 228¢2)

09¢8 (06¢9 - 12¢9)

82¢3 (58¢9 - 108¢7)

-19¢5 (-21¢7 - -11¢3)

-0¢1 (-0¢3 - 0¢0)

-53¢3 (-61¢1 - -42¢4)

-3¢1 (-4¢0 - -2¢1)

YLDs

13¢3 (02¢7 - 27¢0)

210¢9 (42¢9 - 429¢3)

16¢2 (03¢7 - 33¢7)

137¢7 (30¢7 - 285¢9)

22¢5 (16¢7 - 24¢8)

0¢1 (0¢0 - 0¢2)

-34¢7 (-48¢5 - -23¢4)

-2¢4 (-4¢8 - -0¢4)

Andean Latin America
Bolivia

Ecuador
Prevalence 60¢6 (14¢6 - 104¢9)

646¢9 (156¢5 - 1113¢2)

114¢9 (30¢8 - 190¢3)

659¢7 (177¢4 - 1089¢2)

89¢7 (81¢4 - 110¢3)

1¢8 (0¢5 - 2¢8)

2¢0 (-2¢2 - 13¢3)

0¢4 (0¢2 - 0¢8)

Deaths

298¢6 (247¢3 - 324¢9)

3¢3 (2¢8 - 3¢6)

333¢7 (257¢8 - 468¢3)

1¢9 (1¢5 - 2¢7)

11¢8 (4¢3 - 44¢1)

0¢0 (0¢0 - 0¢12)

-40¢7 (-45¢4 - -23¢7)

0¢0 (-0¢1 - 0¢1)

DALYs

40¢9 (22¢4 - 65¢4)

414¢4 (220¢4 - 668¢9)

51¢6 (25¢1 - 87¢5)

293¢2 (142¢1 - 496¢3)

26¢4 (12¢1 - 33¢8)

0¢4 (0¢1 - 0¢7)

-29¢2 (-35¢5 - -15¢8)

-4¢0 (-5¢8 - -2¢6)

YLLs

17¢6 (14¢5 - 19¢3)

169¢3 (140¢5 - 184¢3)

16¢5 (12¢7 - 23¢9)

92¢4 (71¢1 - 133¢3)

-6¢0 (-12¢3 - 24¢2)

0¢0 (-0¢1 - 0¢2)

-45¢4 (-49¢4 - -27¢7)

-2¢6 (-3¢3 - -1¢7)

YLDs

23¢3 (05¢2 - 47¢6)

245¢1 (55¢4 - 498¢6)

35¢2 (8¢8 - 69¢4)

200¢8 (49¢9 - 395¢7)

50¢9 (45¢9 - 69¢8)

0¢4 (0¢1 - 0¢7)

-18¢1 (-29¢8 - -10¢6)

-1¢5 (-3¢4 - -0¢4)

Prevalence 97¢7 (24¢5 - 168¢8)

459¢7 (119¢2 - 786¢3)

153¢3 (39¢3 - 256¢5)

452¢9 (116¢6 - 754¢8)

56¢9 (52¢0 - 60¢3)

1¢9 (0¢5 - 2¢9)

-1¢5 (-7¢2 - -0¢4)

-0¢2 (-0¢5 - 0¢0)

Deaths

1¢9 (1¢4 - 2¢2)

288¢2 (205¢7 - 392¢5)

0¢8 (0¢6 - 1¢1)

-24¢4 (-27¢9 - -11¢2)

0¢0 (0¢0 - 0¢21)

-56¢3 (-68¢3 - -38¢9)

0¢0 (-0¢1 - 0¢1)

Peru
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381¢2 (285¢4 - 441¢8)

DALYs

59¢7 (31¢5 - 96¢6)

271¢6 (141¢4 - 440¢3)

59¢5 (24¢6 - 112¢2)

174¢6 (71¢8 - 328¢1)

-0¢3 (-21¢9 - 16¢1)

0¢0 (-0¢2 - 0¢5)

-35¢7 (-49¢2 - -25¢5)

-3¢2 (-3¢7 - -2¢3)

YLLs

22¢7 (17¢1 - 26¢3)

99¢9 (74¢5 - 115¢9)

14¢1 (09¢9 - 19¢5)

40¢5 (28¢6 - 56¢1)

-38¢0 (-42¢1 - -25¢9)

-0¢3 (-0¢5 - -0¢0)

-59¢4 (-61¢6 - -51¢6)

-2¢0 (-2¢5 - -1¢5)

YLDs

37¢0 (09¢0 - 72¢6)

171¢8 (41¢5 - 336¢7)

45¢4 (10¢6 - 96¢3)

134¢1 (31¢5 - 283¢6)

22¢8 (17¢9 - 32¢7)

0¢3 (0¢1 - 0¢8)

-21¢9 (-34¢2 - -15¢8)

-1¢3 (-1¢8 - -0¢3)

Prevalence 173¢9 (42¢4 - 314¢4)

530¢9 (130¢2 - 951¢1)

258¢2 (70¢1 - 431¢4)

537¢1 (146¢2 - 899¢6)

48¢4 (37¢2 - 65¢3)

2¢8 (0¢9 - 3¢9)

1¢2 (-5¢4 - 12¢3)

0¢2 (-1¢5 - 0¢7)

Deaths

529¢9 (453¢9 - 561¢6)

1¢7 (1¢5 - 1¢8)

647¢7 (497¢7 - 835¢1)

1¢3 (1¢0 - 1¢7)

22¢2 (9¢6 - 48¢7)

0¢0 (0¢0 - 0¢1)

-24¢9 (-34¢0 - -7¢7)

0¢0 (-0¢1 - 0¢1)

DALYs

92¢8 (44¢9 - 166¢4)

275¢3 (131¢6 - 500¢3)

102¢7 (46¢6 - 186¢5)

214¢5 (96¢8 - 390¢1)

10¢7 (3¢8 - 12¢1)

0¢3 (0¢1 - 0¢7)

-22¢1 (-36¢5 - -18¢0)

-2¢0 (-3¢7 - -1¢2)

YLLs

31¢6 (26¢3 - 33¢9)

91¢2 (77¢5 - 97¢1)

31¢4 (24¢1 - 40¢8)

65¢6 (50¢4 - 85¢3)

-0¢5 (-8¢3 - 20¢4)

0¢0 (-0¢1 - 0¢2)

-28¢1 (-34¢9 - -12¢2)

-0¢9 (-1¢9 - -0¢4)

Central Latin America
Colombia

(continued on next page)
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Table 1 (Continued)
1990
Number (in
thousands) (95% UI)
YLDs

61¢2 (13¢9 - 134¢6)

Age standardized rate
(by 100 000 population) (95% UI)

2019
Number (in
thousands)
- (95% UI)

Changes
Age standardized rate
(by 100 000
population) - (95% UI)

Percentage change
for numbers (95% UI)

Annualised rate of
change, 1990−2019
(in numbers)

Percentage change
for rates (95% UI)

Annualised
rate of change,
1990−2019 (in rates)

184¢1 (41¢4 - 406¢5)

71¢3 (15¢9 - 156¢4)

148¢9 (32¢8 - 327¢2)

16¢5 (15¢0 - 26¢2)

0¢3 (0¢1 - 0¢7)

-19¢1 (-22¢8 - -12¢5)

-1¢2 (-2¢6 - -0¢3)

Prevalence 14¢3 (3¢3 - 25¢1)

481¢6 (110¢7 - 838¢2)

25¢8 (07¢5 - 41¢2)

543¢74 (159¢9 - 874¢2)

80¢6 (64¢0 - 130¢7)

0¢4 (0¢1 - 0¢5)

12¢9 (4¢3 - 44¢4)

2¢1 (1¢6 - 3¢2)

Deaths

39¢7 (36¢7 - 42¢3)

1¢6 (1¢5 - 1¢7)

61¢7 (46¢6 - 78¢8)

1¢2 (0¢9 - 1¢5)

55¢2 (27¢1 - 86¢2)

0¢0 (0¢0 - 0¢09)

-25¢8 (-37¢4 - -11¢5)

0¢0 (-0¢1 - 0¢1)

DALYs

6¢4 (2¢9 - 11¢4)

214¢6 (99¢1 - 385¢7)

9¢6 (4¢0 - 17¢4)

199¢5 (82¢1 - 364¢2)

50¢6 (40¢5 - 52¢3)

0¢1 (0¢0 - 0¢2)

-7¢1 (-17¢1 - -5¢6)

-0¢5 (-0¢7 - -0¢2)

Costa Rica

YLLs

1¢9 (1¢9 - 2¢1)

69¢2 (64¢5 - 74¢0)

2¢6 (1¢9 - 3¢4)

51¢6 (39¢0 - 67¢1)

30¢3 (5¢1 - 57¢0)

0¢0 (0¢0 - 0¢1)

-25¢4 (-39¢5 - -9¢3)

-0¢6 (-0¢8 - -0¢2)

YLDs

4¢4 (0¢9 - 9¢5)

145¢4 (29¢8 - 316¢1)

6¢9 (1¢6 - 14¢8)

147¢9 (33¢9 - 310¢4)

59¢7 (56¢4 - 79¢4)

0¢1 (0¢0 - 0¢2)

1¢7 (-1¢8 - 13¢8)

0¢1 (-0¢1 - 0¢2)

Prevalence 20¢2 (4¢9 - 38¢0)

381¢9 (91¢1 - 709¢2)

28¢4 (7¢2 - 48¢3)

449¢9 (112¢7 - 762¢4)

40¢2 (27¢0 - 44¢2)

0¢3 (0¢1 - 0¢6)

17¢8 (7¢5 - 23¢8)

2¢3 (0¢7 - 2¢8)

Deaths

74¢3 (63¢1 - 82¢4)

1¢6 (1¢4 - 1¢7)

69¢6 (51¢6 - 91¢7)

1¢1 (0¢8 - 1¢5)

-6¢4 (-18¢3 - 11¢3)

0¢0 (0¢0 - 0¢1)

-27¢7 (-39¢4 - -12¢9)

0¢0 (-0¢1 - 0¢1)

DALYs

11¢9 (6¢0 - 21¢1)

219¢4 (110¢0 - 382¢7)

11¢8 (4¢9 - 21¢7)

186¢1 (78¢6 - 342¢0)

-1¢7 (-17¢9 - 2¢5)

0¢0 (0¢0 - 0¢1)

-15¢2 (-28¢5 - -10¢6)

-1¢1 (-3¢0 - -0¢4)

YLLs

4¢5 (3¢6 - 5¢1)

80¢8 (67¢8 - 89¢7)

03¢1 (2¢3 - 4¢1)

49¢6 (36¢8 - 65¢7)

-30¢6 (-35¢6 - -18¢4)

0¢0 (0¢0 - 0¢0)

-38¢5 (-45¢7 - -26¢8)

-1¢0 (-2¢0 - -0¢8)

YLDs

7¢5 (1¢7 - 16¢3)

138¢6 (30¢8 - 300¢1)

08¢6 (1¢8 - 18¢2)

136¢5 (28¢9 - 288¢9)

15¢7 (9¢1 - 22¢0)

0¢0 (0¢0 - 0¢1)

-1¢6 (-6¢4 - -0¢7)

-0¢1 (-0¢8 − 0¢0)

Prevalence 34¢8 (07¢4 - 66¢7)

453¢3 (97¢7 - 871¢4)

84¢6 (22¢1 - 147¢5)

479¢9 (126¢5 - 828¢3)

143¢3 (127¢5 - 151¢1)

1¢7 (0¢5 - 2¢7)

5¢9 (-4¢9 - 29¢5)

0¢9 (0¢5 - 1¢4)

Deaths

254¢0 (215¢0 - 285¢5)

3¢7 (3¢2 - 4¢2)

443¢1 (346¢3 - 565¢5)

2¢7 (2¢2 - 3¢5)

74¢4 (61¢1 - 98¢1)

0¢0 (0¢0 - 0¢1)

-26¢2 (-33¢1 - -15¢9)

0¢0 (-0¢1 - 0¢1)

DALYs

29¢8 (18¢6 - 46¢4)

372¢9 (229¢4 - 578¢5)

52¢8 (29¢9 - 83¢4)

292¢5 (164¢5 - 465¢7)

77¢1 (60¢6 - 79¢6)

0¢8 (0¢4 - 1¢2)

-21¢6 (-28¢3 - -15¢5)

-2¢7 (-3¢8 - -1¢2)

El Salvador

Guatemala

YLLs

15¢6 (12¢9 - 17¢6)

191¢1 (161¢9 - 214¢9)

24¢4 (19¢0 - 31¢5)

133¢8 (104¢5 - 171¢3)

56¢6 (46¢7 - 78¢9)

0¢3 (0¢2 - 0¢5)

-30¢0 (-35¢5 - -20¢3)

-1¢9 (-2¢9 - -1¢5)

YLDs

14¢2 (02¢8 - 30¢7)

181¢8 (35¢6 - 388¢5)

28¢3 (5¢9 - 58¢7)

158¢7 (33¢4 - 324¢9)

99¢7 (91¢5 - 115¢5)

0¢5 (0¢1 - 0¢9)

-12¢7 (-16¢4 - -6¢3)

-0¢8 (-2¢1 - -0¢1)

Prevalence 24¢5 (5¢0 - 46¢0)

536¢5 (109¢7 - 995¢6)

49¢3 (13¢4 - 84¢5)

514¢8 (139¢6 - 869¢6)

101¢4 (83¢6 - 167¢1)

0¢8 (0¢3 - 1¢3)

-4¢0 (-12¢6 - 27¢2)

-0¢7 (-4¢2 - 0¢2)

Deaths

4¢2 (3¢4 - 4¢9)

239¢3 (165¢9 - 332¢5)

3¢2 (2¢3 - 4¢4)

45¢1 (30¢7 - 73¢7)

0¢0 (0¢0 - 0¢1)

-22¢9 (-32¢8 - -11¢0)

0¢0 (-0¢1 - 0¢1)

Honduras
164¢9 (126¢9 - 191¢4)

DALYs

19¢7 (11¢7 - 30¢2)

415¢9 (245¢8 - 635¢4)

27¢2 (13¢6 - 45¢3)

288¢9 (147¢2 - 472¢9)

38¢2 (15¢9 - 50¢0)

0¢3 (0¢1 - 0¢5)

-30¢5 (-40¢1 - -25¢6)

-4¢2 (-5¢4 - -3¢3)

YLLs

10¢1 (7¢5 - 11¢9)

209¢1 (160¢8 - 243¢2)

10¢7 (7¢1 - 15¢3)

118¢7 (79¢9 - 167¢6)

6¢2 (-5¢7 - 28¢7)

0¢0 (0¢0 - 0¢1)

-43¢2 (-50¢3 - -31¢1)

-3¢0 (-3¢7 - -2¢5)

YLDs

9¢6 (1¢9 - 19¢8)

206¢8 (40¢9 - 423¢9)

16¢5 (3¢8 - 34¢2)

170¢2 (39¢4 - 351¢7)

71¢8 (63¢1 - 99¢4)

0¢2 (0¢1 - 0¢5)

-17¢7 (-27¢0 - -3¢6)

-1¢2 (-2¢4 - 0¢0)

Prevalence 552¢5 (391¢2 - 746¢8)

661¢9 (472¢4 - 888¢2)

778¢4 (549¢8 - 1020¢2)

627¢2 (443¢9 - 820¢6)

40¢9 (36¢6 - 46¢6)

7¢5 (5¢3 - 9¢1)

-5¢3 (-7¢6 - -2¢0)

-1¢2 (-2¢3 - -0¢9)

Deaths

1834¢5 (1604¢5 - 1933¢6)

2¢5 (2¢2 - 2¢6)

2166¢3 (1857¢7 - 2563¢3)

1¢8 (1¢5 - 2¢1)

18¢1 (15¢8 - 32¢6)

0¢0 (-0¢1 - 0¢0)

-29¢4 (-32¢6 - -19¢8)

0¢0 (-0¢1 - 0¢1)

DALYs

307¢5 (226¢9 - 419¢8)

356¢5 (263¢8 - 476¢5)

331¢9 (238¢1 - 450¢0)

266¢3 (190¢9 - 360¢1)

7¢9 (5¢0 - 9¢2)

0¢8 (0¢4 - 1¢0)

-25¢3 (-30¢6 - -20¢4)

-3¢0 (-3¢9 - -2¢4)

YLLs

108¢6 (92¢0 - 116¢5)

122¢9 (107¢2 - 130¢1)

102¢0 (88¢4 - 119¢7)

81¢4 (70¢5 - 94¢8)

-6¢0 (-9¢0 - 2¢8)

-0¢2 (-0¢3 - 0¢0)

-33¢8 (-39¢2 - -27¢1)

-1¢4 (-3¢2 - -1¢2)

YLDs

198¢9 (118¢2 - 309¢3)

233¢5 (141¢1 - 354¢9)

229¢9 (133¢9 - 344¢3)

184¢9 (108¢1 - 276¢5)

15¢5 (13¢3 - 21¢3)

1¢0 (0¢5 - 1¢2)

-20¢8 (-33¢4 - -18¢1)

-1¢6 (-3¢1 - -0¢6)

Mexico

(continued on next page)
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Table 1 (Continued)
1990
Number (in
thousands) (95% UI)

Age standardized rate
(by 100 000 population) (95% UI)

2019
Number (in
thousands)
- (95% UI)

Changes
Age standardized rate
(by 100 000
population) - (95% UI)

Percentage change
for numbers (95% UI)

Annualised rate of
change, 1990−2019
(in numbers)

Percentage change
for rates (95% UI)

Annualised
rate of change,
1990−2019 (in rates)

Nicaragua
Prevalence 16¢2 (3¢9 - 31¢2)

415¢4 (101¢4 - 782¢4)

26¢5 (06¢4 - 45¢7)

408¢2 (97¢3 - 695¢8)

63¢3 (46¢5 - 72¢6)

0¢3 (0¢1 - 0¢5)

-1¢7 (-11¢1 - -4¢0)

Deaths

76¢6 (57¢8 - 89¢1)

2¢3 (1¢8 - 2¢5)

77¢7 (62¢3 - 99¢6)

1¢4 (1¢2 - 1¢8)

1¢3 (0¢8 - 8¢8)

0¢0 (-0¢1 - 0¢3)

-36¢4 (-47¢3 - -28¢0)

-0¢2 (-2¢0 - 0¢1)
0¢0 (-0¢1 - 0¢1)

DALYs

10¢9 (5¢9 - 17¢9)

262¢4 (141¢7 - 432¢8)

11¢6 (5¢5 - 20¢8)

178¢7 (84¢9 - 320¢8)

5¢8 (-8¢4 - 16¢0)

0¢0 (-0¢2 - 0¢1)

-31¢9 (-40¢1 - -25¢9)

-2¢8 (-3¢7 - -1¢9)

YLLs

5¢0 (3¢6 - 6¢1)

114¢0 (87¢9 - 130¢5)

3¢7 (2¢9 - 04¢9)

58¢7 (46¢7 - 75¢9)

-26¢1 (-37¢8 - -19¢8)

0¢0 (0¢0 - 0¢1)

-48¢5 (-57¢0 - -41¢8)

-1¢8 (-2¢4 - -1¢0)

YLDs

5¢9 (1¢3 - 12¢9)

148¢3 (31¢2 - 318¢2)

7¢9 (1¢7 - 16¢9)

119¢9 (26¢1 - 258¢7)

33¢0 (31¢4 - 34¢7)

0¢1 (0¢0 - 0¢3)

-19¢1 (-26¢1 - -18¢7)

-0¢9 (-2¢0 - -0¢2)

Prevalence 9¢8 (2¢5 - 17¢3)

415¢4 (103¢5 - 726¢9)

22¢6 (6¢5 - 36¢3)

543¢2 (157¢1 - 871¢7)

131¢7 (109¢5 - 167¢2)

0¢4 (0¢1 - 0¢6)

30¢8 (19¢9 - 51¢8)

4¢3 (1¢8 - 4¢8)

Deaths

28¢9 (26¢7 - 32¢4)

1¢4 (1¢3 - 1¢6)

62¢9 (48¢2 - 81¢2)

1¢5 (1¢2 - 1¢9)

117¢3 (80¢4 - 151¢0)

0¢0 (-0¢2 - 0¢2)

4¢9 (-13¢5 - 24¢4)

0¢0 (-0¢1 - 0¢1)

DALYs

4¢7 (2¢2 - 8¢2)

195¢9 (92¢9 - 342¢8)

9¢0 (04¢3 - 15¢9)

215¢8 (101¢9 - 383¢6)

93¢7 (83¢4 - 104¢9)

0¢1 (-0¢1 - 0¢3)

10¢2 (9¢6 - 11¢9)

0¢7 (0¢3 - 1¢4)

YLLs

1¢5 (1¢3 - 1¢7)

62¢2 (57¢2 - 70¢9)

2¢7 (02¢0 - 3¢5)

64¢6 (48¢6 - 84¢1)

84¢5 (53¢1 - 106¢6)

0¢0 (-0¢1 - 0¢1)

3¢8 (-14¢9 - 18¢5)

0¢1 (-0¢3 - 0¢4)

YLDs

3¢2 (0¢8 - 6¢7)

133¢7 (31¢5 - 280¢2)

6¢3 (01¢6 - 13¢2)

151¢3 (37¢9 - 317¢2)

98¢0 (95¢7 - 110¢3)

0¢1 (0¢0 - 0¢2)

13¢1 (8¢4 - 18¢2)

0¢6 (0¢2 - 1¢2)
-1¢1 (-3¢4 - 0¢7)

Panama

Venezuela
Prevalence 107¢5 (27¢7 - 189¢5)

591¢7 (151¢1 - 1038¢5)

156¢4 (48¢5 - 261¢9)

558¢2 (172¢4 - 936¢9)

45¢5 (38¢2 - 75¢0)

1¢6 (0¢7 - 2¢4)

-5¢6 (-9¢8 - 5¢1)

Deaths

350¢0 (311¢6 - 368¢2)

2¢2 (1¢9 - 2¢3)

527¢2 (389¢8 - 687¢6)

1¢8 (1¢3 - 2¢3)

50¢6 (25¢1 - 86¢7)

0¢0 (0¢0 - 0¢1)

-19¢3 (-32¢3 - 0¢0)

0¢0 (-0¢1 - 0¢1)

DALYs

56¢4 (28¢1 - 95¢9)

306¢4 (154¢0 - 521¢9)

68¢8 (33¢3 - 120¢8)

243¢3 (116¢8 - 430¢9)

22¢1 (18¢5 - 26¢0)

0¢4 (0¢2 - 0¢8)

-20¢6 (-24¢2 - -17¢4)

-2¢1 (-3¢0 - -1¢2)

YLLs

18¢9 (16¢9 - 19¢9)

103¢5 (92¢2 - 108¢8)

23¢4 (17¢2 - 30¢5)

80¢7 (59¢6 - 105¢1)

23¢6 (1¢7 - 53¢0)

0¢1 (0¢0 - 0¢4)

-22¢0 (-35¢3 - -3¢4)

-0¢8 (-1¢1 - -0¢1)

YLDs

37¢5 (09¢0 - 76¢7)

202¢9 (50¢3 - 415¢8)

45¢4 (11¢5 - 96¢9)

162¢5 (41¢2 - 349¢2)

21¢3 (17¢6 - 26¢4)

0¢3 (0¢1 - 0¢7)

-19¢9 (-28¢0 - -16¢0)

-1¢3 (-2¢2 - -0¢3)

Prevalence 719¢2 (468¢9 - 993¢7)

500¢8 (325¢9 - 688¢9)

940¢3 (641¢2 - 1245¢9)

429¢9 (291¢5 - 572¢0)

30¢7 (25¢4 - 36¢7)

7¢4 (5¢7 - 8¢4)

-14¢2 (-17¢6 - -11¢0)

-2¢4 (-3¢9 - -1¢1)

Deaths

1¢5 (1¢4 - 1¢5)

2933¢9 (2753¢4 - 3086¢5)

1¢3 (1¢2 - 1¢4)

49¢2 (30¢5 - 48¢2)

0¢0 (-0¢3 - 0¢1)

-11¢6 (-22¢4 - -7¢5)

0¢0 (-0¢1 - 0¢1)

Tropical Latin America
Brazil
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1966¢9 (1829¢4 - 2082¢2)

DALYs

366¢7 (254¢3 - 508¢2)

248¢7 (172¢9 - 342¢6)

404¢2 (287¢9 - 549¢6)

185¢4 (132¢9 - 251¢9)

10¢2 (8¢1 - 13¢2)

1¢2 (1¢1 - 1¢4)

-25¢4 (-33¢2 - -16¢5)

-2¢1 (-3¢0 - -1¢3)

YLLs

114¢4 (104¢9 - 123¢3)

75¢9 (70¢0 - 81¢3)

130¢8 (122¢4 - 139¢6)

59¢9 (55¢3 - 64¢9)

14¢4 (13¢2 - 16¢6)

0¢5 (0¢1 - 0¢8)

-21¢1 (-25¢0 - -10¢2)

-0¢5 (-1¢5 - -0¢2)

YLDs

252¢3 (143¢5 - 392¢7)

172¢8 (98¢9 - 266¢3)

273¢3 (156¢2 - 420¢6)

125¢5 (71¢5 - 193¢8)

8¢3 (7¢1 - 8¢8)

0¢7 (0¢4 - 0¢9)

-27¢4 (-37¢8 - -13¢2)

-1¢6 (-2¢4 - -0¢9)
1¢2 (0¢5 - 1¢4)

Paraguay
Prevalence 14¢8 (3¢3 - 26¢6)

379¢4 (83¢1 - 667¢9)

28¢5 (8¢5 - 46¢9)

414¢9 (124¢4 - 683¢2)

92¢1 (76¢4 - 161¢1)

1¢9 (0¢5 - 2¢9)

9¢3 (2¢3 - 29¢7)

Deaths

50¢3 (44¢1 - 57¢2)

1¢4 (1¢2 - 1¢6)

87¢9 (65¢4 - 113¢8)

1¢3 (0¢9 - 1¢7)

74¢6 (48¢2 - 98¢9)

0¢0 (-0¢1 - 0¢3)

-7¢7 (-21¢1 - 4¢9)

0¢0 (-0¢1 - 0¢1)

DALYs

8¢2 (3¢9 - 14¢1)

205¢9 (96¢9 - 353¢9)

13¢2 (6¢4 - 22¢9)

189¢2 (90¢7 - 328¢1)

60¢0 (34¢6 - 67¢4)

0¢0 (-0¢2 - 0¢5)

-8¢1 (-11¢4 - -5¢3)

-0¢6 (-0¢9 - -0¢2)

YLLs

2¢9 (2¢6 - 3¢3)

71¢3 (61¢9 - 81¢0)

04¢3 (3¢2 - 5¢6)

60¢6 (44¢9 - 78¢7)

48¢6 (25¢3 - 69¢9)

-0¢3 (-0¢5 - -0¢1)

-14¢9 (-27¢4 - -2¢8)

-0¢4 (-0¢6 - -0¢1)

YLDs

5¢3 (1¢0 - 11¢2)

134¢6 (25¢9 - 278¢7)

08¢9 (2¢3 - 18¢7)

128¢6 (33¢5 - 268¢2)

66¢2 (53¢5 - 76¢8)

0¢3 (0¢1 - 0¢8)

-4¢5 (-19¢0 - -3¢8)

-0¢2 (-0¢4 - 0¢3)

Table 1: Burden of idiopathic epilepsy in Latin America by country, in absolute numbers and in age-standardized rates for 1990 and 2019, in both sexes.
UI: uncertainty interval; DALYs, Disability-adjusted life years; YLLs, years of life lost; YLDs, years lived with disability¢
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Risk factor
The only risk quantified in GBD for idiopathic epilepsy was alcohol use, estimated to be responsible for
17¢04 % (95% UI 12¢6 to 21¢8) of the age-standardized DALYs from epilepsy in LAC in 2019. This represents a change of -0¢7% from 1990. The associated
risk was almost double for men (22¢3 %; 95% UI
16¢5 to 28¢1) compared to women (11¢3 %; 95% UI 7¢7
to 15¢1) in 2019. Besides, a higher percentage was
found in people from the 15 to 69 years old cluster
(23¢8 %; 95% UI 17¢6 to 30). Those proportions did
not change from 1990. Finally, the countries with
higher associated risk were Chile, Argentina, and
Paraguay in both 1990 and 2019 (Figure 5).

Correlation analysis
After the Spearman correlation analysis, we found a
negative correlation between the age-standardized rate
of death (rho= -0¢51; p=0¢02), DALYs (rho= -0¢55;
p=0¢01), YLLs (rho= -0¢60; p=0¢007) and YLDs (rho=0¢47; p=0¢04) and the Sociodemographic Index (SDI)
in 1990. In 2019, a similar trend was found for the agestandardized rate of death (rho=-0¢48, p=0¢04), DALYs
(rho= -0¢50, p= 0¢03) and YLL (rho=-0¢50; p= 0¢03) and
SDI (Figure 6), but no for the YLD rate (rho=-0¢35,
p=0¢157). However, we found no statistically significant
correlation among the age-standardized prevalence rate

with the SDI in 1990 (rho=-0¢25; p= 0¢33) and in 2019
(rho=-0¢01; p= 0¢98).

Discussion
Main ﬁndings
From 1990 to 2019, the burden of epilepsy decreased
around 20% in LAC, driven by YLLs reduction; however, the prevalence rate presented no changes for idiopathic epilepsy and an increase for epilepsy with
identifiable aetiology. The burden reduction was higher
in children and adults, but DALYs remained stable for
older adults and even the mortality increased for this
age group. For 2019, we found that 6¢34 million people
live with active epilepsy in LAC (3¢11 million with idiopathic epilepsy and 3¢22 million with epilepsy with identifiable aetiology), representing 8¢1% of the total people
with this diagnosis worldwide. Likewise, LAC countries
concentrated 9¢5% of the total global DALYs for epilepsy, ranking three among the GBD regions (after Central Asia and Sub-Saharan Africa regions).2 The
countries with the highest burden were Ecuador and
Guatemala, and those with the lowest estimates were
Argentina and Uruguay. The current epilepsy burden in
LAC is disability predominant (YLDs rates), mostly in
men compared to women, and in the youth and elderly.
However, the death-related estimates are still elevated

Figure 6. Correlation among burden of disease metrics and SDI in Latin America and the Caribbean in 2019; a) DALYs, b) YLLs, and c)
mortality rate.DALYs, Disability-adjusted life years; YLLs, years of life lost; SDI, socio-demographic index. ARG=Argentina, BOL=Bolivia, BRA=Brazil, CARIB=Caribbean, CHI=Chile, COL=Colombia, COS=Costa Rica, ECU=Ecuador, ELS=El Salvador, GUA=Guatemala,
HON=Honduras, MEX=Mexico, NIC=Nicaragua, PAN=Panama, PAR=Paraguay, PER=Peru, URU=Uruguay, VEN=Venezuela.
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than in other GBD regions,2 of which are higher in
male older adults. Alcohol use is the only available risk
factor for idiopathic epilepsy in LAC, which is associated
with 17% of the reported DALYs. The SDI is an important regional determinant of this burden (higher SDI,
less epilepsy burden, and mortality) but not of the frequency and associated disability of the disease.

Epilepsy prevalence in LAC
We found that the 2019 prevalence rate of all-causes epilepsy in LAC was 8¢17 per 1,000 inhabitants and 4¢12
per 1,000 inhabitants for idiopathic epilepsy. According
to the most recent meta-analysis, the prevalence of
active epilepsy of all causes in LAC was 9¢06 per 1,000
inhabitants,3 which is very close to the GBD study estimates. Besides, it is known that around 40% of the epilepsies are of idiopathic aetiology,19 hence our results
are within what is expected. Also, there was no available
data to calculate the prevalence of epilepsy cases by each
identifiable aetiology. Previous systematic reviews did
not provide a prevalence estimate by the aetiology,3,20
since most primary studies were published prior to the
publication of the 2017 ILAE statement.21 However, it is
known that around 17% of the patients living with epilepsy in LAC have neurocysticercosis (NCC) as the aetiology.3 NCC related epilepsies do not have an
independent entry in the GBD studies, neither as aetiology nor as a risk factor. Hence, there is a need for
improving the real estimate to all causes-active epilepsy
burden in the GBD study. Finally, our results show the
prevalence rate of epilepsy had not changed from 1990
to 2019, which had also been described previously after
cumulative meta-analysis, 3 meaning that the prevalence
estimate is s, thus there are as many new cases as
deceased.

Guatemala and Honduras also had a high rate of
DALYs, but with YLL predominance and the highest
mortality rates. These countries are known for the
health inequities26 presenting the lowest scores of HDI
in the region,27 and high rates of hunger and malnutrition.28 Like Ecuador, NCC is prevalent in these tropical
countries,29 and contributes as an undiagnosed aetiology to the burden.
Besides, the lack of access to proper and timely epilepsy management (pharmacological or surgical) in
these countries,30,31 could explain the high mortality
since improved seizure control by treatment is known
to be the most important measure to prevent SUDEP
and accidents. 32,33 Other causes of early death in people
living with epilepsy in Latin America reported were status epilepticus, brain tumours, stroke, suicide, pneumonia, and sepsis. 30
Finally, the stigma for people with epilepsy in LAC
remains an issue,34 which could impair the willingness
to seek treatment and rehabilitation and increase the
consequent mortality and disability.
Argentina and Uruguay had the lowest prevalence rate
and the lowest burden of epilepsy in terms of DALYs and
both YLD and YLL rates. The prevalence in older adults is
smaller than the other age groups, one possible explanation is that both countries have universal insurance coverage, the highest income of the region, and a better
sanitation system.35 We argue that some conditions intrinsic to this area could be explaining these great differences,
like the southern location far from tropical areas (then less
risk of NCC), 10 and perhaps the smaller rate of endogamy. 36 Also, we found that a great proportion of DALYs
were explained by alcohol use. This opens the possibility
for public health policies to control this risk factor and
lower the burden even more.

The role of the social development index
Insights from country-level data
Ecuador had the highest prevalence rate and had the
highest burden (DALYs) with a YLD predominance.
This means that Ecuador has the greatest burden of epilepsy-related disability. Ecuador belongs to the WHO
epidemiological region D, due to its high overall children and adult mortality rate.22 Around 37% of its population lives in rural settings,23 which is associated with a
higher treatment gap in epilepsy.20
Since there is limited access to neuroimaging or
immuno-assays, many secondary epilepsies are considered idiopathic, including those due to NCC. Still, there
is important underreporting of those diagnosed with
NCC-related epilepsy, mostly from the private health
system.24 Patients with epilepsy in Ecuador had odds to
have NCC three times higher than those without epilepsy.25 Thus, NCC could explain partially the high burden of epilepsy in Ecuador due to case aetiology
underdiagnosis.
14

Prevalence was not correlated with SDI, suggesting that
the index increase itself cannot change the natural history of idiopathic epilepsies. However, the number of
included estimates was small and could be masking a
potential correlation. A positive association between
socioeconomic determinants of health and epilepsy
were reported in previous population-based epidemiological studies in LAC.3
We found that DALYs and YLLs in 1990 and 2019
were lower in countries with higher SDI according to
our correlation analysis, corroborating the global
results.2,37 Economic development contributes toreducing the burden due to mortality reduction, through earlier access to diagnosis and treatment, higher
educational level, and reduction of secondary causes
associated with poor sanitation (such as NCC).3 Countries with lower SDI present higher mortality since a
substantial treatment gap is still present due to lack of
health care resources and treatment availability.2,37,38
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Articles

However, YLDs was lower in countries with higher
SDI in 1990 but not in 2019. These results suggest that
the economic development may only improve epilepsyrelated disability in a limited way since other factors
such as an organized healthcare system, strong primary
care, determinants of medication adherence, successful
self-management, stigma, and work opportunities are
lacking due to political, social, and cultural aspects,
which are independent of only economic growth.39-41

Sex differences
Prevalence and YLDs were not different among men
and women. However, DALYs, YLLs, and mortality are
higher in males. These results are aligned with global
findings.2 Some hypotheses could explain the higher
premature death of men with epilepsy in LAC. First, it
has been shown a higher susceptibility to hyperexcitability events and occurrence of epileptic seizures in men
than women. Changes in seizure sensitivity could be
attributed to steroid hormones,42 including fluctuations
in neurosteroids as well as neuroplasticity in their receptor signalling systems; however, the molecular mechanisms remain unclear.43 Second, men with epilepsy
have more exposure to risk factors and potential causes
of injury,44 such as alcohol use (as we found in our risk
factor analysis),45 labour and traffic accidents,46 and suicide.47 Finally, some studies found a higher incidence of
SUDEP in males,48-50 which may also be associated
with alcohol consumption.48 These factors could
explain the higher burden and mortality of men in LAC.

Age-group differences
In 2019, the burden was higher in the 70+ age group,
while it decreased by 27% for the under 5 years group
and remain still in other group ages. The age-related
burden curve in LAC has three main characteristics: a)
shift to the right (the peaks are later), b) higher estimates in the curve’s valley (especially high YLLS in
adults), c) higher estimates (YLDs and YLLs) in older
adults − the second peak is higher than the first peak
(especially YLDs).
Countries in Latin America had increased their
national income in the past 30 years and improved their
insurance coverage.51 This translated into a lower prevalence of neonatal encephalopathy and hypoxic-ischemic
encephalopathy,52 better maternal-neonatal care,53 and
relative improvement of CNS infections.54 Those factors
could explain the burden reduction in children.
On the other hand, we found no changes for the 70+
group with the highest mortality rate and highest burden for disability.
Since our estimate includes mainly idiopathic epilepsy, the burden in older adults would be underestimated as secondary causes, mostly structural or
metabolic are of high prevalence in this age group.55
Moreover, idiopathic epilepsies are less likely to remit,56
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thus it is expected that prevalence and the overall burden due to disability (YLD) would cumulate in older age
clusters.
When compared to other age groups, epilepsy in
older adults has a higher frequency of acute symptomatic seizures (after an acute brain-altering event), thus
higher prevalence of active epilepsy, and a lower frequency of drug-resistant epilepsy, hence a better seizure
control with AED monotherapy.57 However, there is a
lack of access to treatment in LAC, it has been reported
that the treatment gap in lower- and upper-middleincome countries remains as high as 70%, especially in
rural areas,58 which in LAC represents from 10 to 40%
of all settings.23 Also, the treatment gap could contribute significantly to the mortality estimates in LAC.20
Aging in LAC is a fast-pacing, economic, and social
challenging situation.59 LAC is the region with the largest expected increment in the older adult population
(11.6%) worldwide by 2050.60 Therefore, the proper
diagnosis and timely management of epilepsy in the
elderly is an unattended public health priority in this
ongoing ageing region.

Strengths and limitations
This study is the first regional and country-level assessment of the epilepsy burden in LAC and its changes
over the past 30 years. We report not only the disease
frequency but also the health loss due to epilepsy, allowing us to evaluate the magnitude of epilepsy-related
deaths and disability. However, some limitations need
to be disclosed about the present study. First, this is a
secondary data analysis, so we relied upon the exhaustivity and robustness of a previous research effort,
important limitations of the GBD data include the definition of epilepsy with identifiable aetiology and the
description of epilepsy-related deaths Second, the presence of simulated values for countries with sparse data
could affect the precision of our estimates. Third, there
is no availability of YLLs and mortality data on epilepsy
with identifiable aetiology, the description of most common etiologies, and data on important risk factors such
as sanitation or cysticercosis. Third, some of the points
estimates differences found in our results represented
only a trend since they had overlapping confidence
intervals, such as age-based differences in prevalence
rates, regional differences in DALYs and YLDs rates
and country-based differences in YLLs and YLDs.
Finally, there is a risk of overestimating the idiopathic
epilepsy burden due to diagnostic uncertainty (EEG and
neuroimaging availability) in the region, especially associated with neuro infections (unrecognized neurocysticercosis).

Implications for public health and research
Based on our findings, we encourage urgent public
health actions in LAC. First, since there is a lack of
15
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neurologists especially in the rural areas, most of the
epilepsy care falls on the primary care physicians,
who do not always have the necessary skills. Such a
problem could be addressed throughout a systematic
primary care physician (PCP) training on epilepsy
diagnosis and management in LAC, with a special
focus on late-onset epilepsy. Examples of this strategy
are the mental health GAP program61 and the Latin
American E-learning initiative62 which need further
implementation in the region. However, to make this
solution feasible, online courses should include a
learning network that connects epileptologists and
PCPs. One example of this approach is the ECHO
Ontario program. Second, we suggest the creation of
Epilepsy national programs in LAC following the Pan
American Health Organization (PAHO) recommendations,63 which will help to increase epilepsy awareness and provide guidelines for prevention,
management, and organization of all levels of care
(First level [primary care including rural areas]:
nurses and PCPs; second level [hospitals]: well-trained
general neurologist and internists; third level [specialized center]: epileptologists and specialized neurosurgeons), besides, this program should integrate these
levels using telemedicine tools. Due to the current
COVID-19 pandemic telemedicine reform, this
approach seems to be feasible in the region.64 Besides
the access for specialized physicians, accessing pharmacological and surgical treatments is essential for
adequate epilepsy management, therefore, the availability of antiepileptic drugs in all levels of care
(selecting “classic” and unexpensive drugs such as
valproate or carbamazepine, which have similar efficacy compared to new drugs65) has to be prioritized
during the ongoing health reform in the region.66
Third, we have identified that alcohol use is associated with almost 20% of DALYs in LAC, hence, there
is a need for reinforcement of and collaboration with
current substance abuse prevention programs to
reduce the alcohol consumption in LAC, such as taxation as increased pricing policies as suggested by the
PAHO.67 The stimulation of more mindful and less
use of this substance may lead to a decrease of complications of epilepsy, as SUDEP, and several other
alcohol-related health problems.68 Finally, the prevention of epilepsy as a public health action should
underscore the importance of healthy ageing on the
burden of epilepsy in older people. Some risk factors
in older people that we could target with public health
programs are vascular risk (hypertension, atrial fibrillation, dyslipidemia, and obesity), sleep deprivation,
and medication side effects.55 Therefore, we need to
increase the awareness in general population and
physicians of this risk modification and its impact on
late-onset epilepsy burden, and to include epilepsy
incidence and mortality as metrics of success for
healthy aging programs in the region.
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Conclusion
Over the past 30 years, the epilepsy burden in LAC has
decreased; however, it is still high and contributes significantly to the global epilepsy burden. This burden is
YLD predominant, mostly in the youth and elderly.
However, mortality and premature death are still higher
than in other GBD regions, particularly in male older
adults. Alcohol use is the only available risk factor, and
the SDI is an essential regional determinant for burden
and mortality (higher SDI, less burden). The high mortality and YLLs in the region, mainly in the elderly, suggest a lack of access to adequate pharmacological
treatment. Therefore, there is an urgent need for planning in LAC. This should include prompt access to
treatment in all levels of care, underscoring the
strengthening of primary care and the systematic reduction of stigma and marginalization of people with epilepsy in LAC.
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